Quantcast

Latest gout Stories

2011-06-28 05:30:00

WASHINGTON and DEERFIELD, Ill., June 28, 2011 /PRNewswire/ -- Men's Health Network (MHN) and Takeda Pharmaceuticals North America, Inc., today announced a partnership to launch the "Gout Pit Stop," an educational campaign to raise awareness about gout, a type of arthritis that affects approximately 8.3 million people in the U.S. and is the most common form of inflammatory arthritis in men. Launched just before one of the biggest events of the year on the racing calendar and during Men's...

2011-05-26 14:05:33

A pan-European study of 755 gout patients found that prevalence of self-reported gout was highest in the UK (2.2%) and lowest in France (0.76%). French, German and British gout patients all had lower quality of life scores, and had significant work and social impairment compared to controls (p<0.05 for all comparisons). Interestingly, patients in these countries also had more hypertension, diabetes, congestive heart failure and renal disease (p=0.05) compared to healthy controls. Abstract...

2011-05-26 12:00:00

EAST BRUNSWICK, N.J., May 26, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Marketing Authorization Application (MAA), filed by its wholly owned subsidiary, Savient Pharma Ireland Limited, seeking approval of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy, has completed validation by the European Medicines Agency (EMA). The MAA has been deemed valid by the EMA...

2011-05-25 15:45:00

LONDON, May 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, UK. Results from Primary Dosing Period and Ongoing Extension of Phase 2b Combination...

2011-05-25 00:30:00

EAST HANOVER, N.J., May 25, 2011 /PRNewswire/ -- Novartis announced today results of two pivotal Phase III trials in patients with severe gouty arthritis, showing that ACZ885 (canakinumab) provided superior pain relief and reduced the risk of suffering new attacks by up to 68% compared to an injectable steroid (triamcinolone acetonide, TA) used to treat gouty arthritis attacks(1,2). ACZ885 is an investigational fully human monoclonal antibody. The studies involved more than 450 gouty...

2011-05-19 07:30:00

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and...

2011-05-17 10:00:00

CLEVELAND, May 17, 2011 /PRNewswire/ -- A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans.(1) Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly...

2011-05-09 07:30:00

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011. "Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering...

2011-05-04 17:23:00

EAST BRUNSWICK, N.J., May 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that it has, through its wholly owned subsidiary, Savient Pharma Ireland Limited, delivered via courier to the European Medicines Agency (EMA) and the assigned co-rapporteurs, the Marketing Authorization Application (MAA) for KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Currently there are no EMA...

2011-05-02 12:32:08

The incidence of gout is on the rise and duel energy CT has the potential to allow non-invasive diagnosis of the disease, according to radiologists at the University of British Columbia, Vancouver General Hospital, in Vancouver, BC. Gout is caused by the deposition of monosodium urate (MSU) monohydrate crystals that stimulate acute episodes of inflammation. Chronic tophaceous gout often presents as juxtarticular soft-tissue masses, distinct erosions, overhanging bony margins, and thickening...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related